Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the.

Slides:

Advertisements

Similar presentations

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Advertisements

Drug Treatment of Metastatic Breast Cancer

Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.

Randomized Trial of Preoperative Chemoradiation Versus Surgery Alone in Patients with Locoregional Esophageal Carcinoma, Ursa et al. Statistical Methods:

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.

Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Asymptomatic Individuals With a Positive Family.

CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer Yi-Ying Wu, Yi-Ting Hwang, Wann-Cherng.

Volume 45, Issue 5, Pages (May 2004)

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Combination of Initial Palliative Prognostic Index and Score Change Provides a Better Prognostic Value for Terminally Ill Cancer Patients: A Six-Year.

Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Nicoletta Colombo, Martin Gore

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Volume 112, Pages (October 2017)

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

Fig. 1 Selection of patients

Fig. 1 Flow diagram of patient selection and study design.

Figure 2 Disease-free survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive.

Fig. 1 Esophageal pressure topography of a patient with myotonic dystrophy, pharyngeal salivary stasis, and esophageal dysphagia. Every 5-mL water swallow.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Combination of Initial Palliative Prognostic Index and Score Change Provides a Better Prognostic Value for Terminally Ill Cancer Patients: A Six-Year.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Frequency of cancer in patients operated on for acute peripheral arterial thrombosis and the impact on prognosis Chalotte Winther Nicolajsen, MD, Maja.

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma Isabelle Opitz, MD, Martina Friess,

A B Yeom Supplementary Fig.2

Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.

Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, MB BcH BAO, MRCPI, Min Yuen Teo,

Readmission to Intensive Care Unit After Initial Recovery From Major Thoracic Oncology Surgery Suk-Won Song, MD, Hyun-Sung Lee, MD, PhD, Jae-Hyun Kim,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

Kaplan-Meier curves for overall survival (OS) probability.

Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung.

Volume 67, Issue 1, Pages (January 2005)

Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia S. Terraneo, M. Ferrer, I. Martín-Loeches,

Baseline measure of health-related quality of life (Functional Assessment of Cancer Therapy-Esophagus) is associated with overall survival in patients.

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer Mohammad Chakra, MD, Jean Louis Pujol,

Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care Naitielle de Paula Pantano, RN, Bianca Sakamoto.

Surgical Treatment of Palestinian Patients With Congenital Heart Disease in a Medical Center in Israel: Challenges and Outcome Eldad Erez, Ely Erez,

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Does the Approach Matter

Radioactive Self-Expanding Stents Give Superior Palliation in Patients With Unresectable Cancer of the Esophagus but Should Be Used With Caution if They.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system Victoria A. Kumar, Margo A. Sidell,

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Francisco Alcocer, MD, Marjan Mujib, MD, Bruce Lowman, MD, Mark A

Kaplan–Meier curve for progression-free survival for non-Asian patients with epidermal growth factor receptor (EGFR) mutation-positive status in the INTEREST.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Genomic determinants of response to cytotoxic chemotherapy.

Presentation transcript:

Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the docetaxel group and 3.3 months in the BSC group (P = 0.005). (—) docetaxel group; (---) BSC group. From: Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study Dis Esophagus. 2014;27(8):737-743. doi:10.1111/dote.12246 Dis Esophagus | © 2014 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus

Fig. 2 Hazard ratios for post-progression survival with different combination of covariates between the docetaxel and best supportive care (BSC) groups. CI, confidence interval. From: Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study Dis Esophagus. 2014;27(8):737-743. doi:10.1111/dote.12246 Dis Esophagus | © 2014 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus

Fig. 3 Kaplan–Meier curves of post-progression survival (PPS) according to Glasgow prognostic score (GPS). (a) Median PPSs were 7.1 months (95% confidence interval [CI] 4.4–9.7) in patients with GPS 0, 4.9 months (95% CI 4.3–5.6) with GPS 1, and 2.7 months (95% CI 1.6–3.8) with GPS 2. There were significant differences between the docetaxel and best supportive care (BSC) groups in patients with GPS scores of (b) 0 and (c) 1, but not (d) GPS 2. (a) (—) GPS 0; (---) GPS 1; (-–) GPS 2. (b) GPS 0: (—) docetaxel group; (---) BSC group. Hazard ratio 0.39 (95% CI 0.18–0.86); P = 0.02. (c) GPS 1: (—) docetaxel group; (---) BSC group. Hazard ratio 0.35 (95% CI 0.17–0.75); P = 0.007. (d) GPS 2: (—) docetaxel group; (---) BSC group. Hazard ratio 1.03 (95% CI 0.51–2.07); P = 0.95. From: Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study Dis Esophagus. 2014;27(8):737-743. doi:10.1111/dote.12246 Dis Esophagus | © 2014 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus